Characterization and application of a series of monoclonal antibodies against SARS‐CoV‐2 nucleocapsid protein

Abstract The ongoing coronavirus disease 2019 (COVID‐19) pandemic has a significant global social and economic impact, and the emergence of new and more destructive mutant strains highlights the need for accurate virus detection. Here, 90 monoclonal antibodies (MAbs) that exclusively reacted with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) nucleocapsid protein (NP) were generated. These MAbs did not cross‐react with NPs of common human coronaviruses (HCoVs, i.e., 229E, OC43, HKU1, and NL63) and Middle East Respiratory Syndrome Coronavirus. Subsequently, overlapped peptides in individual fragments (N1–N4) of NP were synthesized. N1‐3 (25‐GSNQNGERSGARSKQ‐39), N3‐1 (217‐AALALLLLDRLNQL‐230), and N4‐8 (393‐TLLPAADLDDFSKQL‐407) were identified as major epitopes using enzyme‐linked immunoassay (ELISA) and recognized by 47, 1, and 18 MAbs, respectively. The 24 remaining MAbs exhibited no reactivity with all synthetic peptides. Among MAb‐epitope pairs, only MAbs targeting epitope N1‐3 displayed no cross‐reaction with NPs of SARS‐CoV‐1 and other SARS‐related CoVs. All Omicron variants contained a three‐amino acid deletion (31ERS33) in the N1‐3 region. Thus, MAbs targeting N1‐3 failed to recognize these variants. Furthermore, a double‐antibody sandwich ELISA for antigen detection was established using the optimal MAbs. Overall, a series of MAbs targeting SARS‐CoV‐2 NP was prepared, characterized with epitope mapping, and applied for the detection of SARS‐CoV‐2 antigens, and some novel B‐cell epitopes of the viral NP were identified.